Ironwood Pharmaceuticals (NASDAQ: IRWD) lists RSU-linked blocks of Class A shares in Form 144

Rhea-AI Filing Summary

Ironwood Pharmaceuticals reported proposed sales of Class A Common Stock on a Form 144, listing multiple blocks of shares tied to restricted stock unit awards. The notice lists amounts including 27,780; 8,905; 8,485; and 6,825 shares associated with RSU awards dated 02/24/2022, 02/23/2023, 02/22/2024, and 01/27/2025.

The entries state each lot is a "Restricted Stock Unit award granted pursuant to the Issuer's 2019 Equity Incentive Plan" (or amended plan) and are shown with vesting requirements. The filing is a routine Rule 144 notice of proposed resale activity and does not disclose sale prices, purchasers, or final transaction timing.

Insights

Equity Capital Markets Analyst

Routine Form 144 lists proposed resale of RSU-related shares; no pricing or proceeds disclosed.

These entries identify specific lots of Class A Common Stock tied to Restricted Stock Unit awards under the company's 2019 Equity Incentive Plan and its amendment. Each line includes the award date and the number of shares associated with that award.

Timing, pricing, and whether the shares will be sold remain undisclosed; subsequent filings or broker reports would show executed trades. The filing itself is administrative and does not indicate issuer proceeds or changes to capital structure.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A Common Stock	E Trade Securities LLC 3 Edison Drive Alpharetta GA 30005	19775	91162.75	162678647	02/23/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A Common Stock	02/24/2022	Restricted Stock Unit award granted pursuant to the Issuer's 2019 Equity Incentive Plan, subject to vesting requirements	Ironwood Pharmaceuticals, Inc.			8485	02/24/2022	N/A
Class A Common Stock	02/23/2023	Restricted Stock Unit award granted pursuant to the Issuer's 2019 Equity Incentive Plan, subject to vesting requirements	Ironwood Pharmaceuticals, Inc.			8905	02/23/2023	N/A
Class A Common Stock	02/22/2024	Restricted Stock Unit award granted pursuant to the Issuer's Amended and Restated 2019 Equity Incentive Plan, subject to vesting requirements	Ironwood Pharmaceuticals, Inc.			6825	02/22/2024	N/A
Class A Common Stock	01/27/2025	Restricted Stock Unit award granted pursuant to the Issuer's Amended and Restated 2019 Equity Incentive Plan, subject to vesting requirements	Ironwood Pharmaceuticals, Inc.			27780	01/27/2025	Nasdaq

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)